Tempus AI (TEM) Soars 21.51% in Six Days, Reaching 2025 High

Tempus AI (TEM) shares surged 0.07% today, marking the sixth consecutive day of gains, with a cumulative increase of 21.51% over the past six days. The stock price reached its highest level since February 2025, with an intraday gain of 4.21%.

The strategy of buying TEM shares after they reached a recent high and holding for one week yielded a 17.22% return over the past five years. This outperformed the benchmark return of 9.26%, with an excess return of 7.95% and a CAGR of 17.52%. The strategy had a Sharpe ratio of 0.14, indicating a reasonable risk-adjusted return. However, it also experienced a maximum drawdown of -61.00% and a volatility of 122.56%, reflecting the risk involved in such a strategy.

Tempus AI's stock price has been volatile in recent months, largely due to legal actions and partnerships. On May 28, 2025, the company's stock plummeted 19.2% following allegations of issuing materially misleading business information. This led to legal actions from firms, highlighting investor concerns about the company's transparency and business prospects.

Despite these challenges, Tempus AI has been actively expanding its partnerships with major companies such as AZN, ILMN, and PSNL. These collaborations are enhancing the company's AI-driven research and development efforts, as well as broadening its reach in precision medicine. This strategic move is expected to bolster the company's technological capabilities and market position.

On June 12, 2025, Tempus AI announced a significant collaboration with Northwestern University's Abrams Research Center on neurogenomics. This partnership aims to leverage AI for Alzheimer's research, which could positively impact the company's stock by advancing its technology and research capabilities in the field of precision medicine. This initiative underscores Tempus AI's commitment to innovation and its potential to make groundbreaking advancements in healthcare.